- An investigation into the death of an 8-year-old Panamanian girl while in custody of the U.S. Border Patrol in Harlingen, Texas, showed that the family was repeatedly denied an ambulance, the U.S. Customs and Border Protection said on Thursday.
The U.S. Food and Drug Administration warned about the safety risks of using compounded or custom-made versions of popular weight-loss drugs such as Wegovy and diabetes drug Ozempic. The health regulator on Wednesday said it had received reports of adverse events after patients used compounded versions of semaglutide, the active ingredient in Danish drugmaker Novo Nordisk's Wegovy and Ozempic.
YS Biopharma Co Ltd (YS): * YS BIOPHARMA'S PIKA RABIES VACCINE RECEIVES PHASE 3 CLINICAL TRIAL APPROVAL FROM PHILIPPINES FDA. * YS BIOPHARMA (YS) - PHASE 3 CLINICAL TRIAL PLANNED TO COMMENCE LATER IN 2023 Source text for Eikon: Further company coverage:
Nexalin Technology Inc (NXL): * NEXALIN TECHNOLOGY, INC. AND WIDER COME LIMITED ANNOUNCE JOINT VENTURE AGREEMENT TO ADVANCE COMMERCIALIZATION OF NEXALIN'S TACS DEVICES IN THE ASIA PACIFIC REGION Source text for Eikon: Further company coverage:
Pfizer Inc (PFE): * U.S. FDA APPROVES ABRYSVO, PFIZER'S VACCINE FOR THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS IN OLDER ADULTS. * Pfizer Inc (PFE) - PFIZER ANTICIPATES SUPPLY AVAILABILITY IN Q3 2023 AHEAD OF ANTICIPATED RSV SEASON THIS FALL.
The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's (PFE) respiratory syncytial virus vaccine for older adults, making it the second shot against the common respiratory disease that can be fatal for seniors. The approval comes less than a month after the FDA approved a similar shot by rival GSK Plc.
Precigen Inc (PGEN): * PRECIGEN RECEIVES FDA CLEARANCE OF IND TO INITIATE PHASE 2 STUDY OF PRGN-2009 OFF-THE-SHELF ADENOVERSE IMMUNOTHERAPY IN COMBINATION WITH PEMBROLIZUMAB TO TREAT PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER Source text for Eikon: Further company coverage:
Rocket Pharmaceuticals Inc (RCKT): * ROCKET PHARMACEUTICALS RECEIVES EUROPEAN MEDICINES AGENCY PRIORITY MEDICINES DESIGNATION FOR RP-A501 GENE THERAPY FOR DANON DISEASE Source text for Eikon: Further company coverage:
CTI Biopharma Corp (CTIC): * CTI Biopharma Corp (CTIC) - HAS CANCELLED 2023 ANNUAL MEETING OF STOCKHOLDERS WHICH WAS SCHEDULED FOR JUNE 21. * CTI Biopharma Corp (CTIC) - HAS WITHDRAWN PROPOSALS TO HAVE BEEN SUBMITTED TO STOCKHOLDERS AT ANNUAL MEETING.
Landos Biopharma Inc (LABP): * LANDOS BIOPHARMA EXPANDS BOARD OF DIRECTORS WITH APPOINTMENT OF ALKA BATYCKY, PH.D. Source text for Eikon: Further company coverage:
News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.
PDF’s require Adobe® Reader® and will open in a new window.
Log In Required
Line of Credit Log In Required